Key Players
Competitive Landscape
ICU nutrition committees choose ventilator-weaning nutrition on tolerance data, protein per litre and fit with existing pumps and protocols, and a listed feed tends to stay for years. As one example, Fresenius Kabi is funding a ventilated-patient trial that links nutrition with mobility, which builds standing with intensivists.[3] Clinical ties of that kind help keep a feed listed once approved.
Pulmonary formula brands compete on respiratory positioning, hospital platforms on full ranges and tender pricing, and protein module makers on flexible top-ups. In addition, Danone's Kate Farms deal added home and retail reach in the United States, so post-discharge supply is becoming a second front.[6] Suppliers without a home channel are likely to lose patients at the point of discharge.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| June 2025: Fresenius Kabi opens enteral R&D center in Gurugram. | Demand for locally adapted enteral feeds. | Regional product development. | Feeds for Asian ICUs. |
| September 2025: Fresenius Kabi funds ventilated ICU nutrition trial. | Protocol-led ICU feeding. | Nutrition linked to early mobility. | Evidence for tailored weaning nutrition. |
| July 2025: Danone completes Kate Farms acquisition. | Care moving from hospital to home. | Combined hospital and home channels. | Post-extubation and home enteral supply. |
Source: Future Market Insights, Ventilator-Weaning Nutrition Market Report, 2026-2036.
Hospital groups now ask suppliers to cover ICU tube feeds and ward supplements under one contract, so full-range suppliers will gain share in tenders.
Who leads the ventilator-weaning nutrition market?
Research presence and sales scale define the leaders. Fresenius Kabi leads ICU nutrition activity in the group, with research funding and new enteral R&D capacity.[3][7] That activity keeps Fresenius Kabi close to ICU protocol decisions. In terms of scale, Nestlé Health Science reports the largest health science sales base, at CHF 6,551 million for 2025.[8] Scale of that order supports broad pulmonary and protein ranges.
Which companies have documented positions?
Research, home reach and group restructuring mark the main positions. Fresenius Kabi holds a position in ICU research and enteral R&D investment.[3][7] Research ties give Fresenius Kabi early sight of new protocols. In the same way, Danone runs the combined US medical nutrition business.[6] Under that roof, a weaning patient can move from Nutricia tube feeds to Kate Farms shakes after discharge. Lastly, Nestlé reports Nestlé Health Science growth and integration plans.[8] Integration into the Nutrition business will reshape how Nestlé serves hospital accounts.
What should buyers evaluate before approving a supplier?
Buyers review tolerance data, protein and energy density, fluid volume and compatibility with pumps and giving sets, then check stock reliability and product codes. For home supply, documentation support for payer claims also decides approval.
How is competition expected to change through 2036?
Suppliers with tube, sip and module formats will take share from single-format brands. Beyond the hospital, home enteral supply will become a larger battleground as more patients leave hospital still weaning.
Representative Company Overview
| Company | Positioning | Recent development |
|---|---|---|
| Fresenius Kabi | Hospital clinical nutrition platform with enteral and ICU ranges | September 2025: EUR 250,000 JUMPstart award for a ventilated ICU trial. |
| Danone Nutricia | Medical nutrition group with Nutricia and Kate Farms ranges | July 2025: Kate Farms majority stake completed. |
| Nestlé Health Science | Medical and consumer health nutrition unit | February 2026: 3.2% organic growth for 2025 reported. |
Research Methodology
The companies included in the report represent current market structure and do not indicate a market-share ranking. Company results, clinical audit bodies, government statistics and trade publications support the analysis, and figures are cross-checked across company, industry and government sources.
